Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Diarrhea Cholera Part A: An individual will be considered eligible for participation in the trial if the following are satisfied: 1. Male or female between 18 and 55 years, inclusive; 2. Female participants are non-pregnant and non-lactating. Female participants of childbearing potential (including perimenopausal women who had menstrual bleeding within the past two years) must use appropriate birth control (abstinence and/or double barrier methods) for 30 days after dosing. Acceptable double barrier methods are the following forms of contraception: condom, contraceptive sponge, hormonal contraceptives, intrauterine devices, and diaphragm or cervical ring with spermicidal gel or foam. Women are considered to be not of childbearing potential if they have been surgically sterilized (physician-documented hysterectomy, bilateral oophorectomy or bilateral tubal ligation). All female participants must have a negative pregnancy test at screening and on admission to the CTU. 3. Written informed consent for participation in the study Part B: A patient will be considered eligible for participation in the trial if the following are satisfied on admission (Day 1) to the hospital: 1. Males aged 18 years to 55 years, inclusive; 2. Duration of illness: History of acute watery diarrhoea of less than 24 hours duration without fever or visible blood in faeces; 3. Clinical signs and symptoms of severe dehydration; 4. A stool Dark-field microscopy or Rapid Strip test demonstrating presence of V. cholerae. 5. Written informed consent for participation in the study  Part A: An individual with any of the following at screening for study enrolment will not qualify for the study: 1. Evidence or history of clinically significant allergic, haematological, immunological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease; or any other condition likely to interfere with the absorption, disposition, metabolism, or excretion of the investigational product; 2. History of cancer with the exception of basal cell or squamous cell (skin) carcinoma; 3. History of drug or alcohol abuse or dependence (based on DSM-IV criteria) within the past two years; 4. Donated blood or plasma, or experienced significant loss of blood within eight weeks prior to admission to the CTU or who plan to donate blood or plasma within one month after study participation; 5. Sustained systolic blood pressure > 140 mmHg or < 95 mmHg or a diastolic blood pressure > 95 mmHg obtained in the seated position; 6. Heart rate at rest of < 40 bpm or > 100 bpm; 7. Clinically significant abnormal ECG findings, as determined by the investigator; 8. Clinically significant abnormal laboratory test results, as determined by the investigator; 9. Currently uses or has used tobacco or nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, etc.) within 30 days prior to admission to the CTU; 10. Evidence or history of any clinically significant illness as per the Investigator's discretion 11. Past history of gastric, small intestinal, or colonic surgery, not including appendectomy or cholecystectomy; 12. Positive HBsAg or anti-HCV Ab; 13. Positive urine test for drug(s) of abuse: benzodiazepines, cocaine, marijuana, methamphetamine, and opiates; 14. Known hypersensitivity to, or intolerance of the excipients in the study medication; 15. Taken over-the-counter (OTC) or prescription medications or herbal supplements (other than hormonal contraceptives, acetaminophen and/or multivitamins [acetaminophen 2gm/day and multivitamins allowed up to 48 hours prior to dosing]) within 14 days; 16. Participants unwilling or unable to take part in this study or refusing to sign informed consent; 17. Participants previously enrolled in this or any other investigational study with the past 30 days. 18. Any current or past condition or laboratory abnormality, which, in the opinion of the investigator, could confound or interfere with evaluation of safety, tolerability, and/or pharmacokinetics of the investigational drug, or prevent compliance with the study protocol Part B: A patient with any of the following at screening for study enrolment will not qualify for the study: 1. History of receiving antimicrobial or anti-diarrhoeal medication (loperamide, diphenoxylate, etc.) within the seven days of admission; 2. Clinically significant abnormal ECG findings, with the exception of sinus tachycardia, premature atrial contractions, or ECG intervals within normal limits for sinus rate; 3. Use of drugs metabolized predominantly via CYP2C93 within seven days of admission; 4. Evidence or history of any clinically significant illness as per the Investigator's discretion 5. Evidence or history of concomitant infection requiring antimicrobial therapy 6. Known hypersensitivity to, or intolerance of iOWH032 or the excipients 7. Past history of gastric, small intestinal, or colonic surgery, not including appendectomy or cholecystectomy 8. Patients unwilling or unable to take part in this study or refusing to sign informed consent 9. Patients previously enrolled in this or any other investigational study with the past 30 days. 10. Any current or past condition or laboratory abnormality, which, in the opinion of the investigator, could confound or interfere with evaluation of safety, tolerability, and/or pharmacokinetics of the investigational drug, or prevent compliance with the study protocol